BNCM: DELEX CORPORATE ACTIONS & EXPANSION PLANS FOR 2026
Press Release
OTC Disclosure & News Service | 02/09/2026
February 2026 — BNCM today provided an update on its ongoing corporate actions and the growth outlook of Delex Healthcare Group, Inc. (DELEX), a profitable pharmaceutical and healthcare company with a strong presence in the Philippines.
Name and Ticker Symbol Change
BNCM has submitted applications for its corporate name change to Delex Healthcare Group and ticker symbol change to DELEX with the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA), respectively. Shareholders will be informed upon receipt of regulatory approvals.
Company Background
Founded in 2009, Delex Pharma International, Inc. has over 15 years of experience developing and distributing affordable, high-quality critical care medications. The company has established one of the most extensive pharmaceutical distribution networks in the Philippines, serving hospitals, pharmacies, and healthcare professionals nationwide.
Management and Market Position
DELEX is led by a seasoned management team with decades of combined experience across local and multinational pharmaceutical companies. Their expertise spans sales, marketing, operations, regulatory affairs, information technology, and human resources.
According to the IQVIA MAT Report, DELEX ranked as the third-largest national pharmaceutical company in the hospital channel in the Philippines as of December 2020.
Current Operations
DELEX currently employs approximately 200 staff, maintains over 30 FDA-approved hospital products, and supplies more than 900 pharmacies and hospitals, 160 drug chains, and 380 dispensing physicians and clinics. The company also operates three pharmacy retail locations.
Key Strengths and Expansion Plans
1. Sustained Growth: Fifteen years of consistent business growth supported by strong leadership, in-demand products, and established regional partnerships.
2. Regulatory Strength: Holder of multiple Philippine FDA licenses covering pharmaceutical importation, distribution, medical devices, cosmetics, food products, and retail drugstores, including online delivery operations.
3. Product Expansion: Portfolio includes over 30 FDA-approved hospital products, with 11 new pharmaceutical launches and expanding medical device offerings.
4. Medical Devices: Strategic alliances with global manufacturers such as Amsino, Masimo, and Verathon to grow its medical device segment.
5. Retail Pharmacy Growth: Plans to expand pharmacy locations to up to 60 stores, strategically located near hospitals and high-traffic areas.
6. ePharmacy Platform: Continued expansion of its 24/7 online pharmacy and delivery services to meet rising digital healthcare demand.
7. Global Engagement: The DELEX ICU Forum, now a global online educational platform, has reached nearly 200,000 healthcare professionals worldwide.
8. Infrastructure & Logistics: Ongoing investments in warehouse expansion, trade sales teams, and SAP ERP systems to enhance operational efficiency.
9. Strategic Acquisition: Acquisition of JMN Brothers Pharma Limited to expand into women’s health and beauty product segments.
10. Quality Assurance: ISO 9001:2015 re-certification, demonstrating commitment to international quality standards.
11. Industry Recognition: Multiple awards, including CEO of the Year 2025, Best Employer Brand Award 2025, and SME Company of the Year.
Market Opportunity
Asia’s pharmaceutical market exceeds US$600 billion, while the medical device market surpasses US$110 billion, driven by population growth, rising healthcare demand, and technological adoption. DELEX is strategically positioned to capture growth through product development, partnerships, and regional expansion.
About DELEX Healthcare Group, Inc. (DELEX)
DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a Delaware-registered company, DELEX partners with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc., bringing high-quality products to market. With a focus on innovation, regulatory excellence, and customer service, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit www.delexpharma.com
Press Release
OTC Disclosure & News Service | 02/09/2026
February 2026 — BNCM today provided an update on its ongoing corporate actions and the growth outlook of Delex Healthcare Group, Inc. (DELEX), a profitable pharmaceutical and healthcare company with a strong presence in the Philippines.
Name and Ticker Symbol Change
BNCM has submitted applications for its corporate name change to Delex Healthcare Group and ticker symbol change to DELEX with the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA), respectively. Shareholders will be informed upon receipt of regulatory approvals.
Company Background
Founded in 2009, Delex Pharma International, Inc. has over 15 years of experience developing and distributing affordable, high-quality critical care medications. The company has established one of the most extensive pharmaceutical distribution networks in the Philippines, serving hospitals, pharmacies, and healthcare professionals nationwide.
Management and Market Position
DELEX is led by a seasoned management team with decades of combined experience across local and multinational pharmaceutical companies. Their expertise spans sales, marketing, operations, regulatory affairs, information technology, and human resources.
According to the IQVIA MAT Report, DELEX ranked as the third-largest national pharmaceutical company in the hospital channel in the Philippines as of December 2020.
Current Operations
DELEX currently employs approximately 200 staff, maintains over 30 FDA-approved hospital products, and supplies more than 900 pharmacies and hospitals, 160 drug chains, and 380 dispensing physicians and clinics. The company also operates three pharmacy retail locations.
Key Strengths and Expansion Plans
1. Sustained Growth: Fifteen years of consistent business growth supported by strong leadership, in-demand products, and established regional partnerships.
2. Regulatory Strength: Holder of multiple Philippine FDA licenses covering pharmaceutical importation, distribution, medical devices, cosmetics, food products, and retail drugstores, including online delivery operations.
3. Product Expansion: Portfolio includes over 30 FDA-approved hospital products, with 11 new pharmaceutical launches and expanding medical device offerings.
4. Medical Devices: Strategic alliances with global manufacturers such as Amsino, Masimo, and Verathon to grow its medical device segment.
5. Retail Pharmacy Growth: Plans to expand pharmacy locations to up to 60 stores, strategically located near hospitals and high-traffic areas.
6. ePharmacy Platform: Continued expansion of its 24/7 online pharmacy and delivery services to meet rising digital healthcare demand.
7. Global Engagement: The DELEX ICU Forum, now a global online educational platform, has reached nearly 200,000 healthcare professionals worldwide.
8. Infrastructure & Logistics: Ongoing investments in warehouse expansion, trade sales teams, and SAP ERP systems to enhance operational efficiency.
9. Strategic Acquisition: Acquisition of JMN Brothers Pharma Limited to expand into women’s health and beauty product segments.
10. Quality Assurance: ISO 9001:2015 re-certification, demonstrating commitment to international quality standards.
11. Industry Recognition: Multiple awards, including CEO of the Year 2025, Best Employer Brand Award 2025, and SME Company of the Year.
Market Opportunity
Asia’s pharmaceutical market exceeds US$600 billion, while the medical device market surpasses US$110 billion, driven by population growth, rising healthcare demand, and technological adoption. DELEX is strategically positioned to capture growth through product development, partnerships, and regional expansion.
About DELEX Healthcare Group, Inc. (DELEX)
DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a Delaware-registered company, DELEX partners with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc., bringing high-quality products to market. With a focus on innovation, regulatory excellence, and customer service, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit www.delexpharma.com
